We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
We finally have some clarity on the release of Q3 results - it looks like it will be the 23rd of June (board meeting taking place on the 22nd)..
>We may get next week but who knows? Morngingstar are saying the 10th of June, but then they've been wrong 4 times already on the Q3 date..
Thanks.
Hi Cyberduck - RNS on 3rd May stated
"Reporting of Q3 financial results is delayed, as sanctioned by the Bangladesh Securities and Exchange Commission."
I believe also the BSEC were short of staff but seemed to have recruited some key players recently (source Dhaka Tribune). We may get next week but who knows? Morngingstar are saying the 10th of June, but then they've been wrong 4 times already on the Q3 date..
Re: the SP on the DSE as I understand it there is a floor on the DSE SPs, i.e. they can't drop below a certain price. I'm no expert in these things but if you knew the floor was say 60tk I could see traders buying sizeable amounts, with no risk, elevating the price and dumping - all risk free as worst case scenario they'd get their money back? Like I say I've not got a good handle on this but if we see the same next week maybe something in it?
I'm pretty sure it's always closed on a Friday but open on Sunday.
look at BXP's website
>closed down yet again in Dhaka
Are you sure? I can't find any announcements.
The market would be closed now anyway because they are ahead of us timewise.
Does anybody know why we haven't had Q3 results yet? Pharma Giles?
closed down yet again in Dhaka...guess you have to accept the wisdom of local crowds/investors
back to base? 30-35p (even though it seems mad...better safe?)
all buys this morning...and a rising sp suggests there isn't yet some largish sell order lurking
(there's even the possibility of a surge of interest: we haven't attracted the attention of the P&D crews yet)
another tick up...slow/sure
yep, seems remarkably good value here in London
if this isn't a fraud (and it would have to be a pretty amazingly elaborate one with faked news articles/photos of major league dignitaries..), it's quite difficult to justify an sp much lower than £1 imv
Just closed up another 7.65% on the Dhaka Exchange. An equivalent of about 69p.
ticking up here now
Nice to see a 10% jump on the Dhaka today (9.88% to be exact), on decent volume..
What was interesting the SKY News interview was BXPs confidence they will get the Remdesivir price down in time. With generics that effectively equates to volume, and lots of it. So I assume they're confident in selling some sizeable amounts down the line.
An area worth watching, I think, are the countries reviewing a "compulsory license" for Remdesivir. As I understand it this can be used in an emergency situation e.g. pandemic, when drug supplies are limited, and allows a country to bypass the existing patent. The state can then buy/manufacture a generic version, and pay the patent holder (Gilead) a royalty - at least that's how I interpret it. But could mean BXP can export into these countries (again as I understand it)?